Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT02330042

OCT Biomarkers for Diabetic Retinopathy

Functional Optical Coherence Tomography-Derived Biomarkers for Diabetic Retinopathy

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
165 (actual)
Sponsor
Oregon Health and Science University · Academic / Other
Sex
All
Age
18 Years – 79 Years
Healthy volunteers
Accepted

Summary

Diabetic retinopathy (DR) is caused by changes in the blood vessels of the retina associated with long-term Type 1 or Type 2 diabetes mellitus. DR is a leading cause of blindness in the United States. Standard optical coherence tomography (OCT) cannot directly detect vascular changes, which may occur early affecting the passage of blood through the tiny capillaries (reduced capillary flow) or cause the greatest damage through formation of abnormal blood vessel growth (neovascularization). Currently, fluorescein angiography (FA) is the gold standard for detecting these changes, but FA requires an injection of a dye into the vein of the arm of the patient. This dye can cause undesirable side effects. Recently, OCT has been used to make functional measurements (such as total retinal blood flow among others) and to perform angiography. Thus, functional OCT may provide a useful, alternate way to evaluate diabetic retinopathy.

Conditions

Timeline

Start date
2015-01-26
Primary completion
2020-02-24
Completion
2026-12-01
First posted
2015-01-01
Last updated
2025-09-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02330042. Inclusion in this directory is not an endorsement.